Patents Examined by Thomas S. Heard
  • Patent number: 11123438
    Abstract: A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin ?-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: September 21, 2021
    Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.
    Inventors: Qiang Li, Yuanli Li, Si Chen, Zhu Wang, Zhao Dong, Zirui Li, Xinlu Ma, Lu Yang, Yongjuan Gao, Yuncheng Zheng, Naichao Sun
  • Patent number: 11097010
    Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: August 24, 2021
    Assignee: Ossianix, Inc.
    Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Julia Lynn Rutkowski, Fabrizio Comper, Mykhaylo Demydchuk, Jaroslaw Michal Szary
  • Patent number: 11092596
    Abstract: A group of peptide compounds and their use in identifying molecules that stimulate proteasome or immunoproteasome are disclosed herein.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 17, 2021
    Assignee: Purdue Research Foundation
    Inventors: Darci Jones Trader, Rachel Anne Coleman
  • Patent number: 11090389
    Abstract: A mitochondrial-targeted PARP inhibitor is provided herein, as well as methods of making and using the mitochondrial-targeted PARP inhibitor.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: August 17, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Hulya Bayir, Robert Clark, Tanja Krainz, Peter Wipf
  • Patent number: 11091528
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 17, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Patent number: 11078231
    Abstract: The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 3, 2021
    Assignee: FRESENIUS KABI ONCOLOGY LTD
    Inventors: Walter Cabri, Saswata Lahiri, Govind Singh, Sarbjot Singh Sokhi, Maneesh Kumar Pandey, Raj Narayan Tiwari, Sonu Prasad Shukla
  • Patent number: 11072634
    Abstract: The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseases associated with transglutaminases.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: July 27, 2021
    Assignee: Zedira GmbH
    Inventors: Martin Hils, Ralf Pasternack, Christian Büchold
  • Patent number: 11072642
    Abstract: Analogues of an alternatively spliced form of atrial natriuretic peptide (MANP) that exhibit pGC-A gain of function and can be used to treat cardiorenal and metabolic disease are described herein.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: July 27, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: John C. Burnett, Jr.
  • Patent number: 11046750
    Abstract: This disclosure relates to recombinant or chimeric FVIII proteins, variants, and vectors encoding the proteins containing one or more ancestral mutations. In certain embodiments, one or more protein domains comprise amino acid sequences that are derived from ancestrally reconstructed amino acid sequences. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising the proteins or vectors and related methods of inducing blood clotting.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 29, 2021
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: H. Trent Spencer, Christopher B. Doering, Philip M. Zakas, Eric Gaucher
  • Patent number: 11040108
    Abstract: This invention relates to a conjugate of formula (I): (A-Z1-)n-Q-Z2-D (I), wherein Z1, Z2, Q, A, D, and n are as described herein. This invention also relates to a pharmaceutical composition including a pharmaceutically acceptable carrier and a conjugate of formula (I). This invention also relates to a method making a conjugate of formula (I), and the use of the conjugate for treating cancerous conditions, modulating cell membrane microheterogeneity, stimulating an immunoresponse, and forming a network on or near the inner or outer surface of target cells.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: June 22, 2021
    Assignee: BRANDEIS UNIVERSITY
    Inventors: Huaimin Wang, Bing Xu
  • Patent number: 11033525
    Abstract: Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 15, 2021
    Assignee: BACH BIOSCIENCES, LLC
    Inventors: William W. Bachovchin, Hung-sen Lai, David G. Sanford, Sarah E. Poplawski, Wengen Wu
  • Patent number: 11034745
    Abstract: Analogs for CLR/RAMP receptor ligands are provided that have agonist, superagonist, antagonist or superantagonist activity. The analogs can be selective for one or more CLR/RAMP receptors, or can be pan-specific.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: June 15, 2021
    Assignee: Adepthera LLC
    Inventor: Sheau Yu Teddy Hsu
  • Patent number: 11026933
    Abstract: Disclosed are methods and compositions for the treatment of a proliferative disorder characterized by increased expression of the FOXM1 gene. Exemplary disorders include adenocarcinoma, melanoma, rhabdomyosarcoma, non-small cell lung cancer (NSCLC), head and neck squamous carcinoma, hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, colon carcinoma, basal cell carcinoma, infiltrating ductal breast carcinoma, anaplastic astrocytoma, glioblastoma, pancreatic carcinoma, gastric cancer, acute myeloid leukemia, lung cancer, liver cancer, breast cancer, prostate cancer, a brain cancer. Kits and articles of manufacture comprising compositions for such treatment are also disclosed.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: June 8, 2021
    Assignee: Children's Hospital Medical Center
    Inventors: Vladimir Kalinichenko, Tatiana Kalin
  • Patent number: 11021526
    Abstract: The invention provides Dsg2-derived peptides for inhibiting EMT and/or vasculogenic mimicry and treating and/or preventing angiogenesis-related diseases. Also provided are pharmaceutical compositions comprising the peptide of the invention and methods of using the peptide of the invention in inhibiting EMT and/or vasculogenic mimicry, and treating and/or preventing angiogenesis-related diseases.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 1, 2021
    Assignee: Asclepiumm Taiwan Co., Ltd
    Inventors: Min-che Chen, Chun-wei Chen
  • Patent number: 11001619
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 11, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Patent number: 10993983
    Abstract: Disclosed herein are cyclic peptides that induce cellular autophagy and have significant cell penetration activity. Methods for inducing autophagy and thereby treating various diseases and conditions associated with impaired autophagy are provided.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: May 4, 2021
    Assignees: Trustees of Tufts College, Board of Regents of the University of Texas System
    Inventors: Joshua Kritzer, Beth Levine, Leila Peraro
  • Patent number: 10988527
    Abstract: The present invention relates to a method for preparing a TNFR-Fc fusion protein mixture comprising a target content of hydrophobic chromatogram peak 3, and to a method for adjusting a content of hydrophobic chromatogram peak 3. Specifically, the present invention relates to (a) a method for preparing a TNFR-Fc fusion protein mixture using a hydrophobic interaction chromatograph medium containing an aromatic functional group, which is pre-equilibrated with an equilibration buffer comprising sodium chloride or ammonium sulfate, and a sample comprising a TNFR-Fc fusion protein mixture liquid produced from mammalian cells, and to a method for adjusting the content of hydrophobic chromatogram peak 3 by hydrophobic chromatography using an equilibration buffer containing a predetermined concentration of sodium chloride or ammonium sulfate.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: April 27, 2021
    Assignee: LG CHEM, LTD.
    Inventors: Sang Woo Park, Hwa Young Lee, Soon Woong Choi, Chul Ho Jung
  • Patent number: 10987401
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 27, 2021
    Assignee: Allysta Pharmaceuticals, Inc.
    Inventor: Henry Hsu
  • Patent number: 10981980
    Abstract: Provided herein are new compositions and methods to target and deliver agents to pathological areas by utilizing multifunctional compounds. These compounds include three or more domains: (i) a vimentin-binding peptide, (ii) a linker, and (iii) a drug binding, a capturing reagent, or a detectable moiety. These compounds can be used to detect, isolate, and/or treat cancerous cells such as circulating tumor cells.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 20, 2021
    Assignee: Counterpoint Biomedica LLC
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Patent number: 10975388
    Abstract: Provided are methods and compositions for delivering a nucleic acid, protein, and/or ribonucleoprotein payload to a cell. Also provided are delivery molecules that include a peptide targeting ligand conjugated to a protein or nucleic acid payload (e.g., an siRNA molecule), or conjugated to a charged polymer polypeptide domain (e.g., poly-arginine such as 9R or a poly-histidine such as 6H, and the like). The targeting ligand provides for (i) targeted binding to a cell surface protein, and (ii) engagement of a long endosomal recycling pathway. As such, when the targeting ligand engages the intended cell surface protein, the delivery molecule enters the cell (e.g., via endocytosis) but is preferentially directed away from the lysosomal degradation pathway.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 13, 2021
    Assignee: LIGANDAL, INC.
    Inventors: Andre Ronald Watson, Christian Foster